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ABSTRACT
Two formulations of pneumococcal vaccines are currently available to prevent invasive disease in adults
and children. However, these vaccines will not protect against the majority of Streptococcus pneumoniae
serotypes. The use of highly conserved cell-wall-associated proteins in vaccines may circumvent this
problem. A proteomics approach was used to identify 270 S. pneumoniae cell-wall-associated proteins,
which were then screened in a process that included in-silico, in-vitro and in-vivo validation criteria.
Five potential candidates for inclusion in a vaccine were selected, expressed in Escherichia coli, and
purified for use in immunisation experiments. These proteins were detected in at least 40 different
serotypes of S. pneumoniae, and were expressed in S. pneumoniae isolates causing infection. Two of the
five candidate proteins, the putative lipoate protein ligase (Lpl) and the ClpP protease, resulted in a
reduced CFU titre and a trend towards reduced mortality in an animal sepsis model for investigating
new S. pneumoniae protein vaccines.
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INTRODUCTION
Infectious diseases caused by bacteria continue to
cause significant morbidity and mortality world-
wide. Streptococcus pneumoniae is the most com-
mon aetiological agent causing lower respiratory
tract infection, meningitis and septicaemia in
humans of all age groups [1]. According to
WHO estimates, at least 700 000 to 1 million
children die each year from pneumococcal respi-
ratory infections worldwide [2]. Currently, two
formulations of pneumococcal vaccines are avail-
able: a 23-valent polysaccharide vaccine and a
heptavalent protein–polysaccharide conjugate
vaccine. These vaccines have proven useful
in preventing invasive disease in adults and
children, respectively, but each has limitations
that may reduce their long-term effectiveness.
In addition, the current adult vaccine includes 23
purified capsular polysaccharides of S. pneumo-
niae (from among the 90 known serotypes), and is
only moderately effective because of poor immu-
nogenicity in high-risk groups (i.e., children aged
<2 years and the elderly). The seven-valent poly-
saccharide–protein conjugate vaccine has been
shown to be immunogenic in young children and
is able to elicit protection against invasive infec-
tion [3]. Nevertheless, S. pneumoniae is highly
diverse with respect to its capsular types, and
this vaccine will not protect against strains of the
many capsular types not included in the vaccine
[4,5].
Failure to cover all polysaccharide types is an
even greater problem, as clinically important
infections in adults are caused by strains with a
large variety of capsular types. An additional
concern is that the polysaccharide–protein conju-
gate vaccines are not easy to manufacture and are
therefore expensive. Proteins that are antigeni-
cally conserved across clinically relevant sero-
types would be more effective immunogens, and
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would potentially be more cost-effective. One
such candidate protein is the pneumococcal sur-
face protein A (PspA), which is an immunogenic
protein expressed on the surface of all strains of
S. pneumoniae. PspA induces antibodies that pro-
tect against invasive infection in mice [6,7]. PspA
is localised on the pneumococcal envelope of each
strain, and exhibits only moderate variability
among strains at the DNA and protein sequence
level [8]. PspA is expressed during the course of
invasive infection and is an effective vaccine in a
murine pneumococcal sepsis model [9]. ABC
transporter proteins PiuA and PiaA are also
promising candidates for a novel S. pneumoniae
protein vaccine. It has been demonstrated that
these two proteins protect mice against systemic
S. pneumoniae infection [10]. Other interesting
candidates are pneumolysin and CbpA, which
have both demonstrated protection against
S. pneumoniae in animal tests [11].
Several different strategies have been utilised
for the detection of candidates for a protein-based
pneumococcal vaccine. For example, a whole
genome approach revealed six protective antigens
[12]. More recently, a group A streptococcus
surface proteome approach was used to identify
new protein vaccine candidates [13]. The present
study also used a proteomics strategy. More than
270 putative S. pneumoniae surface proteins were
identified using a combination of one-dimen-
sional (1-D) or two-dimensional (2-D) PAGE and
mass-spectrometry (MS) and an in-solution digest
together with MS analysis. Five protein candi-
dates for inclusion in a vaccine were selected and
recombinant proteins were expressed in Escheri-
chia coli. The five recombinant proteins were then
tested in an animal sepsis model for investigating
new S. pneumoniae protein vaccines.
MATERIALS AND METHODS
Mice
Six-week-old BALB ⁄ c mice were housed under specific
pathogen-free conditions and given sterile food and water
ad libitum.
Bacteria
E. coli Top10 strain (Invitrogen, Taastrup, Denmark) was used
as the host for routine plasmid cloning. Recombinant proteins
were expressed in E. coli BL21 ⁄ (DE3) (Invitrogen). E. coli
strains were cultured in Luria broth supplemented with
appropriate antibiotics. Virulent S. pneumoniae strains D39
and 49619 (kindly provided by M. Trombe, CICT, Toulouse,
France) were used for proteomics analysis. Strain D39 was
used for the challenge experiment and as a source of genomic
DNA for PCR experiments. Clinical isolates of S. pneumoniae,
including 40 serotypes responsible for the majority of recent
worldwide pneumococcal infections, were selected and pur-
chased from the WHO Collaborating Centre for Reference and
Research on Pneumococci (Copenhagen, Denmark). S. pneu-
moniae strains were grown routinely on blood agar plates
(Difco, Brøndby, Denmark).
Isolation of S. pneumoniae cell-envelope fraction
Mutanolysin digestion of the pneumococcal cell wall. Bacteria were
grown overnight on blood agar plates, harvested into phos-
phate-buffered saline (PBS) containing sucrose 20% w ⁄v and
pelleted by centrifugation at 6000 g for 10 min. The pellet was
resuspended in 0.5 mL of osmotic digestion buffer containing
sucrose 20% w ⁄v in 20 mM Tris-HCl, pH 7.0, 10 mM MgCl2,
protease inhibitor cocktail (Roche, Mannheim, Germany) and
mutanolysin (Sigma, Brøndby, Denmark) 100 U ⁄mL. Enzymic
digestion was allowed to proceed for 1–2 h at 37C. The intact
protoplasts were removed by centrifugation at 7000 g for
15 min. The supernatant was collected, precipitated with
acetone and analysed using MS.
Elution of cell-wall-associated proteins at high pH. Bacteria were
grown overnight on blood agar plates, harvested into PBS
containing sucrose 20% w ⁄v and pelleted by centrifugation at
6000 g for 10 min. The pellet was resuspended in PBS
containing sucrose 20% w ⁄v and centrifuged again as above.
The bacteria were then resuspended in 2 mL of 50 mM
glycine–NaOH (pH 12) containing sucrose 20% w ⁄v. Alkaline
extraction of cell-wall-associated proteins was allowed to
proceed for 30 min at room temperature with gentle shaking.
The suspension was then centrifuged at 15 000 g for 20 min,
and the supernatant was collected, adjusted to pH 7 with 1 M
HCl, precipitated with acetone and analysed by 1-D and 2-D
gel electrophoresis.
Identification of cell-wall-associated proteins
The complex mixture of proteins obtained after surface
extraction was analysed by three complementary strategies,
all based on MS: (i) a 2-D gel-based strategy; (ii) a 1-D
gel-based strategy; and (iii) an in-solution digest strategy.
Unless otherwise indicated, chemicals were purchased from
Sigma.
2-D gel-based strategy. Two-dimensional gel electrophoresis
was performed either on the Ettan Dalt 2 system (Amersham
Biosciences, Hillerod, Denmark) or on the Novex NuPage
system (Invitrogen), according to the instructions of the
respective manufacturer. In brief, first-dimension runs were
performed on either 7- or 24-cm precast strips (pH range 3–10
or 4–7) using the Ettan IPGphor isoelectric focusing system
(Amersham Biosciences) according to the manufacturer’s
instructions. Isoelectric focusing was performed using
8000 Vh for 7-cm strips and 52 000 Vh for 24-cm strips. The
second dimension was performed using precast 12.5% w ⁄v
gels (Amersham Biosciences) with 5 W ⁄ gel for 15 min, fol-
lowed by a total of 170 W for 4–6 h for 24-cm strips. The 7-cm
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strips were run on the Novex NuPage system (Invitrogen)
using precast 4–12% gels (Invitrogen) at 200 V for 40 min. Gels
were silver-stained according to the modified method de-
scribed by Mortz et al. [14], and spots (gel plugs) for MS
analysis were picked and placed in Milli-Q water using the
Ettan Spot Picker (Amersham) according to the manufacturer’s
instructions.
The selected gel plugs were washed in 50 mMNH4HCO3 in
ethanol 50% v ⁄v, and were then dehydrated by incubation in
ethanol 96% v ⁄v. Reduction and alkylation was performed by
incubating in reducing solution (10 mM dithiothreitol, 50 mM
NH4HCO3) at 56C, followed by incubation at room temper-
ature in the dark in alkylation solution (55 mM iodoacetamide,
50 mM NH4HCO3). Two cycles of washing and dehydration
were then performed before the addition of 5 lL of trypsin
(Promega, Mannheim, Germany) 12.5 ng ⁄uL in 50 mM
NH4HCO3 and acetonitrile 10% v ⁄v. An additional volume
of sodium bicarbonate solution was then added and the
digests were incubated overnight at 37C. Trifluoroacetic acid
was then added to the overnight digest, and this was followed
by incubation with shaking.
Parts of the extract were used in matrix-assisted laser
desorption ⁄ ionisation (MALDI)–time of flight (TOF) peptide
mass fingerprint and MALDI-TOF ⁄TOF analysis (Ultraflex;
Bruker Daltonik, Bremen, Germany), and the resulting peak-
lists were used to search a S. pneumoniae database (ACE
Biosciences, Odense, Denmark). The Mascot search program
and scoring algorithm (Matrix Science, London, UK) was used
for database searching. Peptide mass tolerance was set to
60 ppm and 0.7 Da, respectively. Search parameters were
adjusted to include oxidation of methionine and the addition
of carbamidomethyl groups to cysteine, and trypsin was
allowed to miss one cleavage site ⁄peptide.
1-D gel-based strategy. One-dimensional gel electrophoresis
was performed on a Novex NuPage system (Invitrogen)
according to the manufacturer’s instructions. In brief, precast
bis-Tris 12% w ⁄v gels (Invitrogen), size 8 · 8 cm, 1 mm
thick, were used at 200 V for 60 min in NuPage–MOPS–SDS
running buffer. Gels were silver-stained according to the
modified method described originally by Mortz et al. [14].
Whole lanes were removed using a razorblade in 0.5-cm
gel slices. The gel slices were digested as described above
for the 2-D gel-based strategy, using 20 lL of trypsin
solution.
The extracts were analysed using liquid chromatography
(LC)-MS ⁄MS (Cap-LC and Micromass Ultima TOF MS; Waters
Corp., Milford, MA, USA). Each extract was submitted to a
115-min LC-MS ⁄MS analysis. The peak-lists generated from
the fragmented peptides were used to search a S. pneumoniae
database as described above, but with peptide mass tolerance
set to 200 ppm and 0.4 Da, respectively.
In-solution-based strategy. The protein mixture was resus-
pended in 50 mMNH4HCO3 in acetonitrile 10% v ⁄v, followed
by the addition of 50 lL of trypsin and overnight incubation of
the mixture at 37C. Digestion was then stopped by acidifi-
cation with trifluoroacetic acid (final concentration 1% v ⁄v)
and the products were analysed by LC-MS ⁄MS as described
above for the 1-D-based strategy. Database searches were also
performed as described above.
Detection of genes for protein vaccine candidates in
different S. pneumoniae strains
PCR was used to demonstrate the presence of genes encoding
antigens in clinical isolates of S. pneumoniae. For this purpose,
cells were grown on blood agar and diluted in PBS. Genomic
DNA was prepared from each of 40 pneumococcal strains by
boiling cells at 95C for 5 min. Aliquots of this crude DNA
extract were used as templates for PCR amplification using
gene-specific primers (Table 1). Amplification products were
detected following electrophoresis through agarose 1% w ⁄v
gels and visualisation by staining with ethidium bromide
(0.5 mg ⁄L).
RT-PCR
A BALB ⁄ c mouse was infected with S. pneumoniae D39 as
described below. One day after infection, the mouse was
killed humanely and the spleen was extracted and divided
into two. One half was frozen quickly in liquid nitrogen and
stored at )80C before isolation of intact total bacterial RNA.
The other half was cultured for viable bacteria on blood agar
plates. Total RNA was isolated from animal tissue contain-
ing S. pneumoniae with an RNeasy Kit (Qiagen, Hilden,
Germany). First-strand cDNA synthesis was performed
using total RNA and an iScript Kit (Bio-Rad, Herlev,
Denmark); the subsequent PCR step used 1 lL of cDNA
with gene-specific primers (Table 1).
Table 1. Selected antigens used for animal tests and the primers used for PCR detection of the corresponding genes in
clinical isolates of Streptococcus pneumoniae
Antigen (gene) AnrP number Designation
PCR primers (5¢–3¢)
Forward Reverse
ACE653 AnrP516029 (AE007488) Hydrolase, putative
(Streptococcus pneumoniae TIGR4)
GCAACTGACCTCCAAGAAGC CTACCGCCAGCTCTTCTGTC
ACE029 AnrP230653 (AE007417) Lipoate-protein ligase, putative (Lpl)
(S. pneumoniae TIGR4)
GGTCTACGCGGATTACCAGA TAGCTTGGAAGGACGCATCT
ACE607 AnrP800607 (NC_003098) ATP-dependent CLP protease
(proteolytic subunit) (S. pneumoniae R6)
TTGCTTGCTCTTTGACGTTG TTGATTTCGGCCAATTCTTC
ACE060 AnrP944060 (AE008411) Autoinducer-2 production protein
(S. pneumoniae R6)
ACCGCATCATTATGCTGACA ATTGCCAAACCAGCTGAAAC
ACE097 AnrP313097 (NC_003028) conserved hypothetical protein
(S. pneumoniae TIGR4)
CGAGCACCTCTTAGCCAAAC GCAGAGAAGAGGCTGTGGTC
(sig70) S. pneumoniae rpoD GI: 15458591 AAAGAGTTGGCACTGGCTGT CACGAGTGATAGCCTGACGA
AnrP, in-house protein designation.
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Production of recombinant vaccine candidates
The production of a recombinant vaccine was achieved
following PCR amplification of pneumococcal genes, with
subsequent cloning and expression of the genes in E. coli.
Oligonucleotide primers used in PCR experiments were all
synthesised by MWG Biotech (Ebersberg, Germany). Pneumo-
coccal genes used for protein expression were amplified from
the genomic DNA of S. pneumoniae strain D39 by using the
high-fidelity thermostable DNA polymerase, Platinum Pfx
(Invitrogen). The coding sequence was amplified with primers
that contained the start codon, but excluded the stop codon, of
the open reading frame. The coding sequences used for protein
expression were then cloned into plasmid pET101 (Invitrogen)
using a directional Topo cloning kit (Invitrogen), with E. coli
Top10 as the bacterial host. A plasmid-encoded C-terminal
polyhistidine tag flanks each recombinant protein. For recom-
binant protein expression, each recombinant pET101 plasmid
was subcloned into E. coli strain BL21 (DE3). Recombinant
protein expression was initiated by induction with isopropyl-
b-D-thiogalactopyranoside, and proteins were purified from
the soluble fraction of recombinant E. coli lysates by using
metal affinity chromatography resin and buffers (Invitrogen)
according to the manufacturer’s instructions. Protein concen-
trations were estimated by using the BCA test (Pierce Chemical
Co., Hercules, CA, USA). The recombinant proteins were
dialysed against PBS (Millipore, Hundested, Denmark) and
stored at )80C. Recombinant proteins were identified with
MALDI MS technology after purification.
Challenge of actively immunised mice with pneumococci
BALB ⁄ c mice were used in challenge experiments. For an
antigen-specific vaccination, mice were primed with 25 lg of
each antigen and 100 lg of alum adjuvant (Brenntag Biosector,
Frederikssund, Denmark) on day 0. Animals were boosted
with the same amount of antigen on days 14 and 28. Nine
groups of mice (ten mice per group) were treated as follows: (i)
ACE653, animals were vaccinated with ACE653; (ii) ACE029,
animals were vaccinated with ACE029; (iii) ACE607, animals
were vaccinated with ACE607; (iv) ACE060, animals were
vaccinated with ACE060; (v) ACE097, animals were vaccinated
with ACE097; (vi) untreated, BALB ⁄ c mice were left untreated;
(vii) alum, animals were vaccinated with alum adjuvant only;
(viii) unrelated antigen, animals were vaccinated with the
unrelated cellulose-binding domain (Sigma); and (ix) mix
ACE029, 097, 607, animals were vaccinated with a mixture of
ACE029, ACE097 and ACE607. All vaccines were administered
subcutaneously. The mice were bled on days 0, 21 and 35, and
were challenged on day 35 with S. pneumoniae D39. Individual
sera from each immunised mouse were tested for the presence
of specific antibodies before challenge. Virulent S. pneumoniae
D39, grown on blood agar plates, was prepared for challenge
via the intraperitoneal route in actively immunised mice or
control groups. For challenge infections, each mouse was
injected intraperitoneally with c. 5.5 · 106 CFU of S. pneumo-
niae strain D39 suspended in PBS. The optimal CFU for the
challenge study was calculated after lethal dose estimation in a
previous pilot study with S. pneumoniae strain D39 and
BALB ⁄ c mice (data not shown). This model was adapted from
previous challenge studies with S. pneumoniae [15]. The sur-
vival of mice was monitored for 7 days, at which time the
experiments were terminated.
ELISA for detection of IgG in mouse sera
ELISAs were developed for detection of antigen-specific IgG in
mouse sera at days 0, 21 and 35 after vaccination. Different
ELISA plates were coated with recombinant vaccines (2 lg)
and whole-cell lysates (2 lg) of S. pneumoniae D39. Two-fold
serial dilutions were made from mouse sera as a primary
antibody. The secondary antibody (goat anti-mouse IgG
conjugated with horseradish peroxidase) was diluted 1:5000.
Plates were read at 492 nm following colour development with
O-phenylenediamine. IgG status at days 21 and 35 after
vaccination was compared with IgG status at day 0. ELISA
plates with whole-cell lysates were used for animal tests with
groups 6, 7 and 8. ELISA plates for groups 1–5 were coated
with the corresponding recombinant vaccine candidate (Ta-
ble 1). ELISA plates for group 9 were coated with recombinant
vaccine candidates ACE029, ACE607 and ACE097 (2 lg each).
Protein numbering (AnrP) and statistical analysis
S. pneumoniae protein sequences were derived from public
protein databases or by in-silico translation of predicted open
reading frames of the S. pneumoniae genome. An internal
protein database (ACE Biosciences) assigned AnrP (ACE non-
redundant proteins) numbers to individual S. pneumoniae
proteins. Sequences differing by one or more amino-acids
were assigned different AnrP numbers. ACE numbers are
abbreviations for selected proteins, and contain the name of
the company (ACE) and the last three digits of the AnrP
number. Statistical analyses were performed using SigmaStat
(Mann–Whitney U-tests) (SigmaStat; Systat Software, San Jose,
CA, USA) or t-tests (Microsoft Excel).
RESULTS
In total, 270 different polypeptides were identi-
fied in cell-wall-associated fractions of S. pneumo-
niae (full dataset available from the authors). The
method used identifies polypeptides that are
expressed at a relatively high level. Three differ-
ent strategies were employed for the detection of
isolated S. pneumoniae cell-wall-associated pro-
teins; the numbers of proteins identified by each
strategy are depicted in Fig. 1. Five of the cell-
wall-associated proteins identified were selected
for possible use as a protein vaccine (Table 1).
Each of these proteins had <40% similarity to
proteins from E. coli and humans. Genes of these
five proteins were amplified and cloned into
pET101. Recombinant proteins were expressed
in E. coli as described in Materials and methods.
In total, 40 different pneumococcal strains, rep-
resenting 40 different serotypes, were investigated
by PCR for the presence of the five selected genes.
The results revealed that the five genes were all
present in each of the 40 strains, showing that these
genes were highly conserved among different
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serotypes of S. pneumoniae. RT-PCR confirmed that
all five genes were expressed by S. pneumoniae
during animal infection (Fig. 2).
In order to evaluate the five proteins as
potential components of a vaccine, the protection
efficiency was tested using a mouse sepsis model
(see Materials and methods). Five groups of mice
were immunised with one protein each, and one
group received a combination of three selected
antigens. The immunogenicity of each protein
was tested at days 0, 21 and 35 after the day of the
first vaccination (Fig. 3). The mice produced IgG
against antigens ACE029, ACE060, ACE607 and
ACE653, but no immune response was detected
for ACE097 (Fig. 3). No immune responses
against pneumococcal antigens were detected
among animals in groups 6, 7, 8 (control groups)
and 9 (combination of three antigens). For the
bacterial challenge, each mouse was infected with
S. pneumoniae D39 at day 35 after initial vaccina-
tion. Mice derived from the groups vaccinated
with proteins ACE029 and ACE607 yielded a
lower CFU titre after infection with S. pneumoniae
(Fig. 4). However, significantly prolonged sur-
vival of animals vaccinated with ACE029 or
ACE607 was not observed after infection (data
not shown).
DISCUSSION
The aim of this study was to identify highly
conserved proteins that could form potential
components of a novel pneumococcus protein
GeLC-MS/MS
Total protein ID: 204
Total unique ID: 97
2D-gel MALDI-TOF/TOF
Total protein ID: 174
Total unique ID: 77
ISD-MS/MS
Total protein ID: 52
Total unique ID: 4
9
62
37
2
Fig. 1. Identification of cell-wall-associated Streptococcus
pneumoniae polypeptides by three different strategies based
on mass spectrometry: two-dimensional gel electrophore-
sis (2D-gel MALDI-TOF ⁄TOF), one-dimensional gel elec-
trophoresis (GeLC-MS ⁄MS), and in-solution digestion
(ISD-MS ⁄MS). More than 270 polypeptides were identified,
with 37 proteins being identified by all three methods.
Fig. 2. RT-PCR experiments showing expression of five
selected Streptococcus pneumoniae proteins in BALB ⁄ c mice.
ACE653 (AE007488) hydrolase, putative (S. pneumoniae
TIGR4); ACE029 (AE007417) lipoate-protein ligase,
putative (S. pneumoniae TIGR4); ACE607 (NC_003098),
ATP-dependent CLP protease proteolytic subunit (S. pneu-
moniae R6); ACE060 (AE008411) autoinducer-2 production
protein (S. pneumoniae R6); ACE097 (NC_003028) con-
served hypothetical protein (S. pneumoniae TIGR4); sig70,
S. pneumoniae Sigma70 RNA polymerase (rpoD) (positive
control). +RT, PCR of total RNA sample derived from an
S. pneumoniae-infected mouse spleen following reverse
transcription; )RT, PCR of total RNA sample derived
from an S. pneumoniae-infected mouse spleen without
reverse transcription; N, control PCR with no template.
M
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Fig. 3. IgG titres in mice for five selected Streptococcus
pneumoniae proteins. Titres were defined as the reciprocal
value of the highest dilution that gave an absorbance of
>0.3 units. Mean IgG titres ± SD are shown. Day 0 and
day 21, n = 10; day 35, n = 4. * and §, significantly different
from non-immunised controls (Mann–Whitney U-test,
p <0.05).
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vaccine. Highly conserved surface or cell-wall-
associated proteins are excellent targets for pro-
tein vaccines. Such peptides should be present in
the majority of strains of pneumococci, and it was
demonstrated that genes encoding the five
selected peptides in this study were present in
40 serotypes of S. pneumoniae isolated from
patients. The selected genes were also expressed
during experimental infections in mice.
The determination of the cell-surface localisa-
tion of a S. pneumoniae polypeptide can be
achieved using bioinformatics, but with limita-
tions. It is possible to predict with some degree of
certainty whether secretion occurs via the main
secretion pathway and ⁄ or the location of a pro-
tein, but it is not possible to predict surface
location purely on the basis of primary sequence
characteristics. An alternative strategy for the
identification of potential vaccine candidates is
based on genome sequence and in-silico analysis
[12]. This strategy revealed only a small sub-
population of potential candidate proteins that
conferred protection in a mouse model [12].
However, it is doubtful whether in-silico methods
are reliable for an accurate prediction of mem-
brane or surface proteins. For example, a prote-
omics analysis of the cell-envelope fraction of
E. coli revealed that the grand average hydropho-
bicity scores were insufficient for prediction of a
subcellular location [16], based on the grand
average hydrophobicity values of the identified
proteins, determined according to Kyte and Doo-
little [17], as well as the theoretical transmem-
brane regions, determined according to Klein
et al. [18]. Current knowledge concerning sub-
cellular location is limited, even for well-studied
organisms. Furthermore, it is probable that the
cellular localisation of proteins is difficult to
predict using bioinformatics approaches, since
they can only predict surface locations if location-
related motifs are identified experimentally. Only
a few such motifs are currently known, and many
proteins may localise to the surface via unknown
or as yet unidentified motifs or sequence struc-
tures.
Despite these limitations, many of the proteins
identified in the present study were also recognis-
ed using proteomics approaches in group B and
group A streptococci cell-surface-associated
extracts [19–21]. In this situation, many proteins
do not contain leader sequences or cell-wall
anchors (e.g., enolase). A comparison of the 270
proteins identified in the present study with
published lists of cell-wall-associated proteins
[19–21] revealed glyceraldehyde-3-phosphate
dehydrogenase, enolase (2-phosphoglycerate de-
hydratase) and phosphoglycerate kinase in all
studies. Interestingly, each of these proteins is
predicted to be a ‘cytoplasmic protein’ by Psort
(data not shown), which provides a good example
of the problematic nature of predicting a cellular
localisation by bioinformatics. However, the
present study succeeded in extracting a cell-wall
fraction of S. pneumoniae with mutanolysin or
high-pH treatment, and this strategy seems to be
reliable for the extraction of cell-wall-associated
proteins. Mutanolysin produces stable protoplasts
of S. pneumoniae, with experiments using (3H)thy-
midine and (14C)leucine as cytoplasmic pool
markers revealing only minimal (10%) leakage
Fig. 4. Bacterial counts (CFU ⁄mL in
blood) in mice 6 h after challenge
with Streptococcus.
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during a 1-h incubation period [22]. This is
important, since it is known that cell-wall-associ-
ated protein preparations are usually contami-
nated with cytosolic proteins. The extracted cell-
wall-associated proteins were identified with MS
analysis.
The five proteins selected for the vaccine
efficacy study (Table 1) were highly abundant
proteins that were associated with the S. pneumo-
niae cell-wall, and had not previously been used
in vaccine research. The expression of these
proteins as recombinant proteins in E. coli was
uncomplicated. In contrast to the four other
antigens tested, ACE097 and a mix of ACE029,
ACE097 and ACE607 were not immunogenic, for
unknown reasons. The level of protection given
by these vaccine candidates was tested using a
lethal sepsis model (90–100% mortality in the
controls by day 1) [15]. Half the lethal dose
(LD50) for the D39 strain in this model is
c. 2.0 · 103 CFU ⁄mL (data not shown). Animals
were challenged with 0.5 mL of a
5.5 · 106 CFU ⁄mL suspension, i.e., >1000-fold
the LD50. Unfortunately, it was not possible to
compare the ACE antigens with the existing
Pneumovax vaccine in this animal model of
sepsis, as, in contrast to published results
[23,24], reliable protection of BALB ⁄ c mice against
S. pneumoniae D39 was not achieved using
Pneumovax (data not shown).
The difficulty of obtaining prolonged survival
over several days could also be related to pheno-
typic variations in the S. pneumoniae strain used.
Both opaque and non-opaque colonies were
observed, and these differences could be related
to variations in the pathogenicity of this particular
strain. Further investigation is required to explore
the relationship between these different pheno-
types and protection in animal models. In addi-
tion, the highly protective Prevnar vaccine could
not be used as a control because it does not protect
against serotype 2 (D39). Nevertheless, two
candidate proteins (ACE029 ⁄Lpl, ACE607 ⁄ClpP)
resulted in lower CFU titres at 6 h after challenge
(Fig. 4). The sequences of both proteins were
revealed to be highly conserved after sequencing
of open reading frames from at least six different
S. pneumoniae strains (full sequence data are
available from the authors).
Interestingly, Kwon et al. [25] have also identi-
fied ClpP (ACE607) as a vaccine candidate, and
reported that ClpP elicited a protective immune
response against fatal systemic challenge with
S. pneumoniae D39. Subsequently, enhanced pro-
tection against pneumococcal infection elicited by
immunisation with a combination of ClpP, PspA
and an additional surface protein, PspC, has been
demonstrated [26]. These results support the
findings in the present study concerning
ACE607 ⁄ClpP, and provide evidence for the capa-
bility of the vaccine target identification and
validation platform used in the study. Although
the ACE029 ⁄Lpl homologue of Listeria monocyto-
genes is a known virulence factor [27], little is
known about ACE029 (Lpl). However, based on
the evidence obtained in the present study, it can
be concluded that ACE029 ⁄Lpl and ACE607 ⁄ClpP
are interesting proteins that deserve further eval-
uation as potential vaccine components.
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